|
Market Closed -
Nasdaq Helsinki
12:00:00 2026-08-20 EDT
|
After hours 15:45:36 | |||
| 79.05 EUR | -0.06% |
|
78.88 | -0.22% |
| 08-10 | Orion License Partner Tenax's Pulmonary Hypertension Drug Fails to Improve Walk Distance in Late-stage Trial | MT |
| 08-10 | Orion partner's phase 3 study with levosimendan missed its goals | FW |
Company Valuation: Orion Oyj
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 5,119 | 7,179 | 5,509 | 6,005 | 8,944 | 11,139 | - | - |
| Change | - | 40.25% | -23.26% | 8.99% | 48.95% | 24.55% | - | - |
| Enterprise Value (EV) 1 | 5,010 | 7,060 | 5,603 | 6,126 | 9,088 | 11,050 | 10,806 | 10,536 |
| Change | - | 40.91% | -20.65% | 9.35% | 48.35% | 21.58% | -2.2% | -2.5% |
| P/E | 26.5x | 20.6x | 25.5x | 18.2x | 17.9x | 19.7x | 16.9x | 14.9x |
| PBR | 6.86x | 7.91x | 6.19x | 5.98x | 6.97x | 6.93x | 5.59x | 4.58x |
| PEG | - | 0.3x | -0.7x | 0.3x | 0.3x | 1.6x | 1x | 1.2x |
| Capitalization / Revenue | 4.92x | 5.36x | 4.63x | 3.89x | 4.73x | 5.31x | 4.71x | 4.36x |
| EV / Revenue | 4.81x | 5.27x | 4.71x | 3.97x | 4.81x | 5.27x | 4.57x | 4.12x |
| EV / EBITDA | 17.3x | 14.5x | 17.2x | 12x | 13.2x | 14.3x | 12x | 10.5x |
| EV / EBIT | 20.6x | 16.1x | 20.4x | 14.7x | 14.4x | 15.6x | 13x | 11.3x |
| EV / FCF | 38.5x | 21.7x | 105x | 29.7x | 41.5x | 22.4x | 21x | 16.8x |
| FCF Yield | 2.6% | 4.6% | 0.95% | 3.37% | 2.41% | 4.46% | 4.77% | 5.96% |
| Dividend per Share 2 | 1.5 | 1.6 | 1.62 | 1.64 | 1.8 | 1.945 | 2.168 | 2.47 |
| Rate of return | 4.11% | 3.12% | 4.13% | 3.83% | 2.83% | 2.46% | 2.74% | 3.12% |
| EPS 2 | 1.38 | 2.49 | 1.54 | 2.35 | 3.56 | 4.012 | 4.692 | 5.298 |
| Distribution rate | 109% | 64.3% | 105% | 69.8% | 50.6% | 48.5% | 46.2% | 46.6% |
| Net sales 1 | 1,041 | 1,341 | 1,190 | 1,542 | 1,890 | 2,096 | 2,367 | 2,557 |
| EBITDA 1 | 289.1 | 487.1 | 326.4 | 509.4 | 688.3 | 770.8 | 897.2 | 1,002 |
| EBIT 1 | 243.3 | 439.6 | 274.9 | 416.6 | 631.6 | 707.9 | 828.1 | 933.2 |
| Net income 1 | 193.8 | 349.5 | 216.8 | 329.9 | 500.3 | 564.5 | 660.4 | 746.2 |
| Net Debt 1 | -108.3 | -118.7 | 93.3 | 121.7 | 144.4 | -89.76 | -333 | -603.1 |
| Reference price 2 | 36.52 | 51.24 | 39.27 | 42.78 | 63.65 | 79.10 | 79.10 | 79.10 |
| Nbr of stocks (in thousands) | 140,563 | 140,202 | 140,351 | 140,501 | 140,693 | 140,866 | - | - |
| Announcement Date | 2/10/22 | 2/9/23 | 2/13/24 | 2/25/25 | 2/12/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.72x | 5.27x | 14.34x | 2.46% | 12.99B | |
| 36.57x | 13.2x | 26.79x | 0.54% | 1,141B | |
| 30.41x | - | - | 1.96% | 659B | |
| 33.95x | 7.85x | 16.34x | 2.58% | 470B | |
| 20.47x | 4.85x | 12.03x | 2.72% | 366B | |
| 22.39x | 5.8x | 14.38x | 2.75% | 302B | |
| 21x | 4.33x | 12.29x | 2.03% | 254B | |
| 27.98x | 7.21x | 12.8x | 2.28% | 239B | |
| 13.62x | 4.84x | 10.15x | 3.77% | 207B | |
| -45.1x | 6.51x | 25.42x | 2.23% | 183B | |
| Average | 18.10x | 6.65x | 16.06x | 2.33% | 383.4B | |
| Weighted average by Cap. | 25.78x | 8.62x | 18.93x | 1.89% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ORNBV Stock
- Valuation Orion Oyj
Select your edition
All financial news and data tailored to specific country editions
